TrialCancer communications (London, England)2019

Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.

Sung Yong Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.